Seeking Alpha

Targanta Therapeutics (TARG)

()

Comments on TARG

  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    Last time I checked FDA did not cosider stock valuations in their BLA or PAI approval processes. Since your familiarity with regulatory... More »
    Comment by Seeking Accuracy
    May 1 12:56 pm |
    Rating: 0 0
  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    HGSI should be able to sell albuferon at a lower price per dosage than Pegasys because pegylation is an expensive process. Because it... More »
    Comment by Druglord
    Apr 11 14:55 pm |
    Rating: 0 0
  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    Most reasonable people would consider a 68 percent haircut in one day a failure. On Apr 02 09:45 AM Seeking Accuracy wrote: >... More »
    Comment by Mark Cifra
    Apr 2 10:37 am |
    Rating: 0 0
  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    WHY DID YOU LEAVE 'MRNA' OUT OF YOUR ARTCLE? AFTER ALL, IT IS A NEW COMPANY, NEW CEO, MADE TWO PARTNERING DEALS WITHIN 60 DAYS THIS... More »
    Comment by jimmy Turano
    Apr 2 10:14 am |
    Rating: +1 -4
  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    HGSI's phase 3 trial for albuferon did not fail. In fact, the defined endpoint of non-inferiority was successfully met. The SVR was... More »
    Comment by Seeking Accuracy
    Apr 2 09:45 am |
    Rating: +2 -1
  • Bullish Thesis for Biotech Remains Intact [View article]
    Your article was much appreciated and you couldn't have selected better stocks to confirm your expertise. These are the stocks to be... More »
    Comment by jimmy Turano
    Mar 4 08:45 am |
    Rating: +1 0
  • Updated FDA Calendar: Cypress Bioscience Looks Like a Buy [View article]
    "Eli Lilly (LLY) filed a sBLA for Erbitux to be used in first-line, combination treatment for non-small cell lung cancer" I think that... More »
    Comment by Ax
    Dec 13 11:23 am |
    Rating: 0 0
  • 73 Decision Dates on Updated FDA Calendar [View article]
    But since those examples are history --> Look for major upcoming decisions for small/mid-caps CYPB, PTIE, KG, ALO to name a few that... More »
    Comment by Mike Havrilla
    Nov 24 05:31 am |
    Rating: 0 0
  • 73 Decision Dates on Updated FDA Calendar [View article]
    How about 50% gain or LGND, 103% gain for AMAG, 80% decline for TARG witihin the last few weeks based on either approval decisions or... More »
    Comment by Mike Havrilla
    Nov 24 05:23 am |
    Rating: 0 0
  • 73 Decision Dates on Updated FDA Calendar [View article]
    If its a small market cap company with large short interest exposure, 50% plus would not be uncommon. Thanks for the info, will look... More »
    Comment by NOWHEREMAN
    Nov 23 13:47 pm |
    Rating: 0 0
  • 73 Decision Dates on Updated FDA Calendar [View article]
    Nice to know information but not sure how it relates to investment decisions. Unless a new drug will cause a big move in stock price,... More »
    Comment by BlueOkie
    Nov 23 09:59 am |
    Rating: 0 0
  • The Long Case for Targanta Therapeutics [View article]
    Thanks for a very thorough and thought provoking series
    Comment by DaveC
    Feb 2 18:11 pm |
    Rating: 0 0
  • The Long Case for Targanta Therapeutics [View article]
    Thanks for a very thorough and thought provoking series
    Comment by DaveC
    Feb 1 17:09 pm |
    Rating: 0 0